Perseus Proteomics, Inc. (JP:4882) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Perseus Proteomics, Inc. recently showcased promising results for their radioisotope labeled antibody, PPMX-T002, at the EANM ’24 Congress in Germany. The antibody, designed to target cadherin 3 expressed in various solid tumors, demonstrated enhanced efficacy in preclinical trials when utilizing Actinium 225 over Yttrium 90. This development signals a potential breakthrough in cancer treatment strategies.
For further insights into JP:4882 stock, check out TipRanks’ Stock Analysis page.